Ximluci®

ACTIVE PRINCIPLE:
ranibizumab

INDICATION:
wet macular degeneration
Macular edema
Diabetic retinopathy
diabetic complications

DATE:
22/11/2022

STATUS:
Authorized

MORE INFORMATION